ClinicalTrials.Veeva

Menu

Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy (OPTIMUM)

Y

Yuhan

Status and phase

Completed
Phase 4

Conditions

Diabetic Peripheral Neuropathy

Treatments

Drug: Pregabalin 150mg + Alpha-lipoic acid 480mg
Drug: Pregabalin 150mg
Drug: Alpha-Lipoic Acid 480mg

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

This study is a randomized, parallel, open-label, multicenter, phase IV clinical trial to assess the efficacy and safety of pregabalin and alpha-lipoic acid combination compared with each monotherapy in patients with diabetic peripheral neuropathy for 12 weeks.

Enrollment

151 patients

Sex

All

Ages

19 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • aged 19 to 75
  • type 2 diabetes mellitus with HbA1c (Hemoglobin A1c) ≤ 10 %
  • peripheral (eg. hands, feet) neuropathic pain (eg. abnormal sensations, numbness, pain, etc.) within 3 months (12 weeks)
  • diagnosed with diabetic peripheral neuropathy (DPN)
  • VAS pain score ≥ 40 mm
  • written informed consent

Exclusion criteria

  • brittle diabetes mellitus
  • ALT (Alanine Transaminase), AST (Aspartate Transaminase), CPK (Creatine Phosphokinase) level ≥ 3 times the upper limit of normal (UNL) or active liver disease
  • severe renal impairment (eGFR (estimated glomerular filtration rate) < 60 mL/min/ 1.73m2)
  • treated with antiepileptic drugs within 1 week at randomization
  • other nervous system or neuropathic disorders that may affect pain evaluation
  • oral drug administration is not possible, or hypersensitive or allergic to pregabalin, r-thioctic acid tromethamine, thioctic acid, and other excipients
  • pregnant, lactating, or childbearing potential
  • alcoholics, drug abusers, and patients who are difficult to participate in clinical trials due to psychological and emotional problems
  • have participated in other clinical trials within 30 days at screening

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

151 participants in 3 patient groups

Pregabalin and alpha-lipoic acid combination therapy
Experimental group
Description:
Alpha-lipoic acid 480 mg/tablet once daily before breakfast and Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
Treatment:
Drug: Pregabalin 150mg + Alpha-lipoic acid 480mg
Pregabalin monotherapy
Experimental group
Description:
Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
Treatment:
Drug: Pregabalin 150mg
Alpha-lipoic acid monotherapy
Active Comparator group
Description:
Alpha-lipoic acid 480 mg/tablet once daily before breakfast will be administrated for 12 weeks.
Treatment:
Drug: Alpha-Lipoic Acid 480mg

Trial contacts and locations

14

Loading...

Central trial contact

JC Won

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems